The NLRP3 inflammasome in kidney disease and autoimmunity

Nephrology

Volumn 21, Issue 9, 2016, Pages 736-744

  Hutton, Holly L ^a,b   Ooi, Joshua D ^a   Holdsworth, Stephen R ^a,b   Kitching, A Richard ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b SOUTHERN HEALTH   (Australia)

Author keywords

acute kidney injury; chronic kidney disease; glomerulonephritis; inflammasome; innate immunity

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; NEUTROPHIL CYTOPLASMIC ANTIBODY; URATE;

ACUTE KIDNEY FAILURE; ANCA ASSOCIATED VASCULITIS; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HUMAN; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

EID: 84983558993     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12785     Document Type: Review

References (96)

1. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014; 157: 1013–22.
2. Doria A, Zen M, Bettio S et al. Autoinflammation and autoimmunity: bridging the divide. Autoimmun. Rev. 2012; 12: 22–30.
3. Wen H, Ting JP, O'Neill LA. A role for the NLRP3 inflammasome in metabolic diseases – did Warburg miss inflammation? Nat. Immunol. 2012; 13: 352–7.
4. Hornung V, Bauernfeind F, Halle A et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 2008; 9: 847–56.
5. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237–41.
6. Gris D, Ye Z, Iocca HA et al. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010; 185: 974–81.
7. Kahlenberg JM, Kaplan MJ. The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr. Opin. Rheumatol. 2014; 26: 475–81.
8. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J. Am. Soc. Nephrol. 2011; 22: 1007–18.
9. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140: 805–20.
10. Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013; 13: 397–411.
11. Joosten LA, Netea MG, Dinarello CA. Interleukin-1beta in innate inflammation, autophagy and immunity. Semin. Immunol. 2013; 25: 416–24.
12. Novick D, Kim S, Kaplanski G, Dinarello CA. Interleukin-18, more than a Th1 cytokine. Semin. Immunol. 2013; 25: 439–48.
13. Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 2013; 38: 1142–53.
14. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221–5.
15. Nakahira K, Haspel JA, Rathinam VA et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 2011; 12: 222–30.
16. Iyer SS, He Q, Janczy JR et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 2013; 39: 311–23.
17. Ferrari D, Pizzirani C, Adinolfi E et al. The P2X7 receptor: a key player in IL-1 processing and release. J. Immunol. 2006; 176: 3877–83.
18. Kayagaki N, Warming S, Lamkanfi M et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011; 479: 117–21.
19. Abais JM, Zhang C, Xia M et al. NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia. Antioxid. Redox Signal. 2013; 18: 1537–48.
20. Zhang C, Boini KM, Xia M et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension 2012; 60: 154–62.
21. Lichtnekert J, Kulkarni OP, Mulay SR et al. Anti-GBM glomerulonephritis involves IL-1 but is independent of NLRP3/ASC inflammasome-mediated activation of caspase-1. PLoS One 2011; 6: e26778.
22. Faust J, Menke J, Kriegsmann J et al. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum. 2002; 46: 3083–95.
23. Homsi E, Janino P, de Faria JB. Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int. 2006; 69: 1385–92.
24. Wang J, Wen Y, Lv LL et al. Involvement of endoplasmic reticulum stress in angiotensin II-induced NLRP3 inflammasome activation in human renal proximal tubular cells in vitro. Acta Pharmacol. Sin. 2015.
25. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 2010; 11: 136–40.
26. Gauer S, Sichler O, Obermuller N et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007; 72: 1081–7.
27. Shahzad K, Bock F, Dong W et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015; 87: 74–84.
28. Furuichi K, Wada T, Iwata Y et al. Interleukin-1-dependent sequential chemokine expression and inflammatory cell infiltration in ischemia–reperfusion injury. Crit. Care Med. 2006; 34: 2447–55.
29. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat. Rev. Rheumatol. 2010; 6: 232–41.
30. Haq M, Norman J, Saba SR, Ramirez G, Rabb H. Role of IL-1 in renal ischemic reperfusion injury. J. Am. Soc. Nephrol. 1998; 9: 614–9.
31. Lan HY, Nikolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int. 1993; 43: 479–85.
32. Timoshanko JR, Kitching AR, Iwakura Y, Holdsworth SR, Tipping PG. Contributions of IL-1beta and IL-1alpha to crescentic glomerulonephritis in mice. J. Am. Soc. Nephrol. 2004; 15: 910–8.
33. Jones LK, O'Sullivan KM, Semple T et al. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol. Dial. Transplant. 2009; 24: 3024–32.
34. Wu H, Craft ML, Wang P et al. IL-18 contributes to renal damage after ischemia–reperfusion. J. Am. Soc. Nephrol. 2008; 19: 2331–41.
35. Bani-Hani AH, Leslie JA, Asanuma H et al. IL-18 neutralization ameliorates obstruction-induced epithelial-mesenchymal transition and renal fibrosis. Kidney Int. 2009; 76: 500–11.
36. Kitching AR, Turner AL, Wilson GR et al. IL-12p40 and IL-18 in crescentic glomerulonephritis: IL-12p40 is the key Th1-defining cytokine chain, whereas IL-18 promotes local inflammation and leukocyte recruitment. J. Am. Soc. Nephrol. 2005; 16: 2023–33.
37. Melnikov VY, Ecder T, Fantuzzi G et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. 2001; 107: 1145–52.
38. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A. 2009; 106: 20388–93.
39. Faubel S, Ljubanovic D, Reznikov L, Somerset H, Dinarello CA, Edelstein CL. Caspase-1-deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. Kidney Int. 2004; 66: 2202–13.
40. Kim HJ, Lee DW, Ravichandran K et al. NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J. Pharmacol. Exp. Ther. 2013; 346: 465–72.
41. Chan AJ, Alikhan MA, Odobasic D et al. Innate IL-17A-producing leukocytes promote acute kidney injury via inflammasome and toll-like receptor activation. Am. J. Pathol. 2014; 184: 1411–8.
42. Goncalves RG, Gabrich L, Rosario A, Jr., Takiya CM, Ferreira ML, Chiarini LB et al. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int. 2006; 70: 1599–606.
43. Vilaysane A, Chun J, Seamone ME et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J. Am. Soc. Nephrol. 2010; 21: 1732–44.
44. Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. Mediators Inflamm. 2009; 2009: 137072. DOI:10.1155/2009/137072
45. Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008; 73: 1008–16.
46. He Z, Lu L, Altmann C et al. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury. Am. J. Physiol. Renal Physiol. 2008; 295: F1414–21.
47. Anders HJ, Schaefer L. Beyond tissue injury-damage-associated molecular patterns, toll-like receptors, and inflammasomes also drive regeneration and fibrosis. J. Am. Soc. Nephrol. 2014; 25: 1387–400.
48. Babelova A, Moreth K, Tsalastra-Greul W et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 2009; 284: 24035–48.
49. Liu D, Xu M, Ding LH et al. Activation of the Nlrp3 inflammasome by mitochondrial reactive oxygen species: a novel mechanism of albumin-induced tubulointerstitial inflammation. Int. J. Biochem. Cell Biol. 2014; 57: 7–19.
50. L'Homme L, Esser N, Riva L et al. Unsaturated fatty acids prevent activation of NLRP3 inflammasome in human monocytes/?macrophages. J. Lipid Res. 2013; 54: 2998–3008.
51. Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004; 114: 1752–61.
52. Haneklaus M, O'Neill LA. NLRP3 at the interface of metabolism and inflammation. Immunol. Rev. 2015; 265: 53–62.
53. Nakamura A, Shikata K, Hiramatsu M et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890–5.
54. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 2006; 11: 226–31.
55. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004; 65: 116–28.
56. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am. J. Physiol. Renal Physiol. 2011; 301: F1358–66.
57. Mirza RE, Fang MM, Weinheimer-Haus EM, Ennis WJ, Koh TJ. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice. Diabetes 2014; 63: 1103–14.
58. Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury. Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol. Dial. Transplant. 2014; 29: 507–14.
59. Isaka Y, Takabatake Y, Takahashi A, Saitoh T, Yoshimori T. Hyperuricemia-induced inflammasome and kidney diseases. Nephrol. Dial. Transplant. 2015. DOI:10.1093/ndt/gfv024.
60. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015; 16: 58.
61. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J. Am. Soc. Nephrol. 2008; 19: 2407–13.
62. Emmerson BT, Cross M, Osborne JM, Axelsen RA. Reaction of MDCK cells to crystals of monosodium urate monohydrate and uric acid. Kidney Int. 1990; 37: 36–43.
63. Kim SM, Lee SH, Kim YG et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2015; 308: F993–f1003.
64. Wang C, Pan Y, Zhang QY, Wang FM, Kong LD. Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation. PLoS One 2012; 7: e38285.
65. Mulay SR, Kulkarni OP, Rupanagudi KV et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1beta secretion. J. Clin. Invest. 2013; 123: 236–46.
66. Knauf F, Asplin JR, Granja I et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int. 2013; 84: 895–901.
67. Ooi JD, Chang J, Hickey MJ et al. The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc. Natl. Acad. Sci. U. S. A. 2012; 109: E2615–24.
68. Okamoto A, Fujio K, Tsuno NH, Takahashi K, Yamamoto K. Kidney-infiltrating CD4+ T-cell clones promote nephritis in lupus-prone mice. Kidney Int. 2012; 82: 969–79.
69. Salama AD, Chaudhry AN, Ryan JJ et al. In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J. Am. Soc. Nephrol. 2001; 12: 1908–15.
70. Ooi JD, Chang J, O'Sullivan KM et al. The HLA-DRB1*15:01-restricted Goodpasture's T cell epitope induces GN. J. Am. Soc. Nephrol. 2013; 24: 419–31.
71. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann. N. Y. Acad. Sci. 2010; 1183: 211–21.
72. Summers SA, Steinmetz OM, Gan PY et al. Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis. Arthritis Rheum. 2011; 63: 1124–35.
73. Summers SA, Steinmetz OM, Li M et al. Th1 and Th17 cells induce proliferative glomerulonephritis. J. Am. Soc. Nephrol. 2009; 20: 2518–24.
74. Shin MS, Kang Y, Lee N et al. Self double-stranded (ds)DNA induces IL-1beta production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies. J. Immunol. 2013; 190: 1407–15.
75. Kahlenberg JM, Carmona-Rivera C, Smith CK, Kaplan MJ. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J. Immunol. 2013; 190: 1217–26.
76. Zhang W, Cai Y, Xu W, Yin Z, Gao X, Xiong S. AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J. Clin. Immunol. 2013; 33: 925–37.
77. Pontillo A, Girardelli M, Kamada AJ et al. Polimorphisms in inflammasome genes are involved in the predisposition to systemic lupus erythematosus. Autoimmunity 2012; 45: 271–8.
78. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 4115–9.
79. Hewins P, Morgan MD, Holden N et al. IL-18 is upregulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int. 2006; 69: 605–15.
80. Hultgren O, Andersson B, Hahn-Zoric M, Almroth G. Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis. Autoimmunity 2007; 40: 529–31.
81. Schreiber A, Pham CT, Hu Y, Schneider W, Luft FC, Kettritz R. Neutrophil serine proteases promote IL-1beta generation and injury in necrotizing crescentic glomerulonephritis. J Am Soc Nephrol. 2012; 23: 470–82.
82. Belizna CC, Hamidou MA, Levesque H, Guillevin L, Shoenfeld Y. Infection and vasculitis. Rheumatology (Oxford) 2009; 48: 475–82.
83. Kessenbrock K, Krumbholz M, Schonermarck U et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 2009; 15: 623–5.
84. O'Sullivan KM, Lo CY, Summers SA et al. Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Kidney Int. 2015; 88: 1030–46.
85. Gatenby PA. Anti-neutrophil cytoplasmic antibody-associated systemic vasculitis: nature or nurture? Intern. Med. J. 2012; 42: 351–9.
86. Deplano S, Cook HT, Russell R et al. P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis. J. Leukoc. Biol. 2013; 93: 127–34.
87. Sugiyama M, Kinoshita K, Kishimoto K, Shimazu H, Nozaki Y, Ikoma S et al. Deletion of IL-18 receptor ameliorates renal injury in bovine serum albumin-induced glomerulonephritis. Clin Immunol. 2008; 128: 103–8.
88. Schorlemmer HU, Kanzy EJ, Langner KD, Kurrle R. Immunoregulation of SLE-like disease by the IL-1 receptor: disease modifying activity on BDF1 hybrid mice and MRL autoimmune mice. Agents Actions 1993; 39 Spec No: C117–20.
89. Zhao J, Wang H, Dai C et al. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/?ASC/caspase 1 pathway. Arthritis Rheum. 2013; 65: 3176–85.
90. Kahlenberg JM, Yalavarthi S, Zhao W, Hodgin JB, Reed TJ, Tsuji NM et al. An essential role of caspase 1 in the induction of murine lupus and its associated vascular damage. Arthritis Rheumatol. 2014; 66: 152-62.
91. Chen A, Sheu LF, Chou WY et al. Interleukin-1 receptor antagonist modulates the progression of a spontaneously occurring IgA nephropathy in mice. Am. J. Kidney Dis. 1997; 30: 693–702.
92. Levy M, Thaiss CA, Elinav E. Taming the inflammasome. Nat. Med. 2015; 21: 213–5.
93. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu. Rev. Med. 2014; 65: 223–44.
94. Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015; 21: 263–9.
95. Perregaux DG, McNiff P, Laliberte R et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J. Pharmacol. Exp. Ther. 2001; 299: 187–97.
96. Coll RC, Robertson AA, Chae JJ et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015; 21: 248–55.